{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:50:26Z","timestamp":1792482626414,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T00:00:00Z","timestamp":1524182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["M008665"],"award-info":[{"award-number":["M008665"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s40262-018-0658-1","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T06:10:00Z","timestamp":1524204600000},"page":"53-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children"],"prefix":"10.1007","volume":"58","author":[{"given":"Sophida","family":"Boonsathorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iek","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kloprogge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmion","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilyana","family":"Doncheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chiesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-7173","authenticated-orcid":false,"given":"Joseph F.","family":"Standing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,20]]},"reference":[{"key":"658_CR1","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","volume":"100","author":"KA Marr","year":"2002","unstructured":"Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358\u201366.","journal-title":"Blood"},{"key":"658_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/00006454-199308000-00009","volume":"12","author":"S Walmsley","year":"1993","unstructured":"Walmsley S, et al. Invasive Aspergillus infections in a pediatric hospital: a ten-year review. Pediatr Infect Dis J. 1993;12:673\u201382.","journal-title":"Pediatr Infect Dis J"},{"key":"658_CR3","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1128\/AAC.46.5.1581-1582.2002","volume":"46","author":"QN Sun","year":"2002","unstructured":"Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46:1581\u20132.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR4","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1128\/AAC.00163-06","volume":"50","author":"F Sabatelli","year":"2006","unstructured":"Sabatelli F, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50:2009\u201315.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1368-5031.2004.00167.x","volume":"58","author":"R Herbrecht","year":"2004","unstructured":"Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract. 2004;58:612\u201324.","journal-title":"Int J Clin Pract"},{"key":"658_CR6","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1086\/503425","volume":"42","author":"II Raad","year":"2006","unstructured":"Raad II, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42:1398\u2013403.","journal-title":"Clin Infect Dis"},{"key":"658_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348\u201359.","journal-title":"N Engl J Med"},{"key":"658_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10096-010-0957-4","volume":"29","author":"T Lehrnbecher","year":"2010","unstructured":"Lehrnbecher T, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis. 2010;29:1043\u20135.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"658_CR9","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1086\/375075","volume":"36","author":"AM Tobon","year":"2003","unstructured":"Tobon AM, Arango M, Fernandez D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis. 2003;36:1488\u201391.","journal-title":"Clin Infect Dis"},{"key":"658_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/INF.0000000000000963","volume":"35","author":"K Vanstraelen","year":"2016","unstructured":"Vanstraelen K, et al. Pharmacokinetics of posaconazole oral suspension in children dosed according to body surface area. Pediatr Infect Dis J. 2016;35:183\u20138.","journal-title":"Pediatr Infect Dis J"},{"key":"658_CR11","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","volume":"69","author":"HR Ashbee","year":"2014","unstructured":"Ashbee HR, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69:1162\u201376.","journal-title":"J Antimicrob Chemother"},{"key":"658_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bcp.13160","volume":"83","author":"E Germovsek","year":"2017","unstructured":"Germovsek E, Barker CI, Sharland M, Standing JF. Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful? Br J Clin Pharmacol. 2017;83:777\u201390.","journal-title":"Br J Clin Pharmacol"},{"key":"658_CR13","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1128\/AAC.00222-12","volume":"56","author":"G Krishna","year":"2012","unstructured":"Krishna G, Ma L, Martinho M, O\u2019Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56:4196\u2013201.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR14","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1093\/jac\/dks268","volume":"67","author":"G Krishna","year":"2012","unstructured":"Krishna G, Ma L, Martinho M, Preston RA, O\u2019Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012;67:2725\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"658_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","volume":"44","author":"F Ezzet","year":"2005","unstructured":"Ezzet F, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet. 2005;44:211\u201320.","journal-title":"Clin Pharmacokinet"},{"key":"658_CR16","volume-title":"NONMEM user\u2019s guides. (1989\u20132013)","author":"S Beal","year":"2013","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user\u2019s guides. (1989\u20132013). Ellicott City: Icon Development Solutions; 2013."},{"key":"658_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"key":"658_CR18","unstructured":"R Core Team R. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2015. \n                    https:\/\/www.R-project.org\/\n                    \n                  . Accessed 7 Apr 2018."},{"key":"658_CR19","doi-asserted-by":"publisher","unstructured":"Petitcollin A, et al. Population pharmacokinetics of posaconazole tablets and Monte Carlo simulations to determine whether all patients should receive the same dose. Antimicrob Agents Chemother. 2017;61. \n                    https:\/\/doi.org\/10.1128\/aac.01166-17\n                    \n                  .","DOI":"10.1128\/aac.01166-17"},{"key":"658_CR20","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1128\/AAC.03777-14","volume":"58","author":"MJ Dolton","year":"2014","unstructured":"Dolton MJ, Bruggemann RJ, Burger DM, McLachlan AJ. Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. Antimicrob Agents Chemother. 2014;58:6879\u201385.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR21","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00432-017-2369-7","volume":"143","author":"M Doring","year":"2017","unstructured":"Doring M, et al. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2017;143:1281\u201392.","journal-title":"J Cancer Res Clin Oncol"},{"key":"658_CR22","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1128\/AAC.00496-15","volume":"59","author":"U Durani","year":"2015","unstructured":"Durani U, et al. Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension. Antimicrob Agents Chemother. 2015;59:4914\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/myc.12587","volume":"60","author":"S Welch","year":"2017","unstructured":"Welch S, et al. Comparison of serum concentrations between different dosing strategies of posaconazole delayed-release tablet at a large academic medical centre. Mycoses. 2017;60:241\u20133.","journal-title":"Mycoses"},{"key":"658_CR24","first-page":"3460892","volume":"2017","author":"M Belling","year":"2017","unstructured":"Belling M, et al. Evaluation of serum posaconazole concentrations in patients with hematological malignancies receiving posaconazole suspension compared to the delayed-release tablet formulation. Leuk Res Treat. 2017;2017:3460892.","journal-title":"Leuk Res Treat"},{"key":"658_CR25","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","volume":"47","author":"R Courtney","year":"2003","unstructured":"Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003;47:2788\u201395.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","volume":"50","author":"AJ Ullmann","year":"2006","unstructured":"Ullmann AJ, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50:658\u201366.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR27","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1128\/AAC.00157-06","volume":"50","author":"PO Gubbins","year":"2006","unstructured":"Gubbins PO, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother. 2006;50:1993\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR28","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1128\/AAC.05937-11","volume":"56","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, et al. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother. 2012;56:2652\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3109\/00365521.2014.898326","volume":"49","author":"HF Helander","year":"2014","unstructured":"Helander HF, Fandriks L. Surface area of the digestive tract - revisited. Scand J Gastroenterol. 2014;49:681\u20139.","journal-title":"Scand J Gastroenterol"},{"key":"658_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/10408440390242324","volume":"33","author":"PS Price","year":"2003","unstructured":"Price PS, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol. 2003;33:469\u2013503.","journal-title":"Crit Rev Toxicol"},{"key":"658_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1128\/AAC.01027-09","volume":"54","author":"V Kohl","year":"2010","unstructured":"Kohl V, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010;54:207\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR32","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1128\/AAC.01034-08","volume":"53","author":"G Krishna","year":"2009","unstructured":"Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53:958\u201366.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR33","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2165\/11592630-000000000-00000","volume":"50","author":"J Walravens","year":"2011","unstructured":"Walravens J, et al. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet. 2011;50:725\u201334.","journal-title":"Clin Pharmacokinet"},{"key":"658_CR34","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1592\/phco.28.10.1223","volume":"28","author":"G Krishna","year":"2008","unstructured":"Krishna G, et al. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy. 2008;28:1223\u201332.","journal-title":"Pharmacotherapy"},{"key":"658_CR35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1086\/597110","volume":"48","author":"JW Alffenaar","year":"2009","unstructured":"Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009;48:839.","journal-title":"Clin Infect Dis"},{"key":"658_CR36","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.3748\/wjg.v11.i26.4067","volume":"11","author":"WH Wang","year":"2005","unstructured":"Wang WH, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol. 2005;11:4067\u201377.","journal-title":"World J Gastroenterol"},{"key":"658_CR37","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1046\/j.1365-2036.1997.00195.x","volume":"11","author":"U Armbrecht","year":"1997","unstructured":"Armbrecht U, Abucar A, Hameeteman W, Schneider A, Stockbrugger RW. Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole\u2014comparison of 24-hour intragastric and oesophageal pH. Aliment Pharmacol Ther. 1997;11:959\u201365.","journal-title":"Aliment Pharmacol Ther"},{"key":"658_CR38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1365-2125.2010.03680.x","volume":"70","author":"HP Lipp","year":"2010","unstructured":"Lipp HP. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol. 2010;70:471\u201380.","journal-title":"Br J Clin Pharmacol"},{"key":"658_CR39","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1128\/AAC.02448-13","volume":"58","author":"WK Kraft","year":"2014","unstructured":"Kraft WK, et al. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58:4020\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"658_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1592\/phco.27.6.825","volume":"27","author":"A Sansone-Parsons","year":"2007","unstructured":"Sansone-Parsons A, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27:825\u201334.","journal-title":"Pharmacotherapy"},{"key":"658_CR41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1185\/03007990802644209","volume":"25","author":"A Moton","year":"2009","unstructured":"Moton A, et al. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin. 2009;25:701\u20137.","journal-title":"Curr Med Res Opin"},{"key":"658_CR42","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00044011-200929070-00006","volume":"29","author":"EM Billaud","year":"2009","unstructured":"Billaud EM, et al. Management of metabolic cytochrome P450 3A4 drug\u2013drug interaction between everolimus and azole antifungals in a renal transplant patient. Clin Drug Investig. 2009;29:481\u20136.","journal-title":"Clin Drug Investig"},{"key":"658_CR43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1365-2125.2006.02778.x","volume":"63","author":"S Hennig","year":"2007","unstructured":"Hennig S, et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol. 2007;63:438\u201350.","journal-title":"Br J Clin Pharmacol"},{"key":"658_CR44","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2165\/00003088-200645110-00004","volume":"45","author":"S Hennig","year":"2006","unstructured":"Hennig S, et al. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet. 2006;45:1099\u2013114.","journal-title":"Clin Pharmacokinet"}],"updated-by":[{"DOI":"10.1007\/s40262-018-0722-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000}}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0658-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0658-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0658-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T10:31:20Z","timestamp":1568716280000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0658-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,20]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["658"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0658-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,20]]},"assertion":[{"value":"20 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"However, the Original article has been updated with the Open Access under Commercial License.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No specific funding was obtained for this project, which was undertaken as part of the Masters thesis of Sophida Boonsathorn. Support at the institutional level came from the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London, and Joseph F. Standing was supported by a United Kingdom Medical Research Council Fellowship (Grant M008665).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Adam Irwin declares research funding and speaker fees from Gilead. Sophida Boonsathorn, Iek Cheng, Frank Kloprogge, Carlos Alonso, Charmion Lee, Bilyana Doncheva, John Booth, Robert Chiesa and Joseph F. Standing have no conflicts of interest directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the institute\u2019s research and development office.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As the study involved the retrospective use of anonymised data, formal participant\/parental consent was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}